To support quality improvement (QI) projects in breast cancer, the Association of Community Cancer Centers (ACCC) has partnered with Pfizer Global Medical Grants to award more than $1.8 million in funding to 15 projects that are aimed at improving the quality of breast cancer patient care. The projects will focus on conducting quality improvement (QI) initiatives that support increasing the rates of BRCA testing for patients with early stage or metastatic breast cancer.
Grants proposals were solicited through a Request for Proposal (RFP) issued by ACCC together with Pfizer Global Medical Grants with the intent of funding QI initiatives that fully integrate BRCA testing into patient care plans in order to help inform the treatment decision-making process.
The grant awards are providing an opportunity for community oncology programs to implement initiatives that will address barriers to counseling and testing. The grantees will utilize innovative approaches to extend best practices to a much larger patient population, including underserved minority patient groups. As part of the initiatives, sites will review their progress and in particular, evaluate how changes in testing practices impact treatment decision-making.
The projects will launch in January 2019 and will continue for two years. In early 2020, ACCC will begin sharing the results from these QI projects.
Supported by a grant from Pfizer, Inc.
Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018 - via OBR